Developer docs
API playgroundTry for free, no card

Search company profiles

Alpha Biopharma

Full company profile

uuid0002eq4

Namestring
Alpha Biopharma
Legal namestring
江苏晨泰医药科技有限公司
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Alpha Biopharma (晨泰医药 / Jiangsu Chentai Pharmaceutical Technology Co., Ltd.) is a China-based, privately held clinical-stage biopharmaceutical company founded in 2017. It specializes in innovative oncology drugs from clinical development through commercialization, with operations concentrated in mainland China (offices in Shanghai and Beijing; ICP-registered in Jiangsu) and a headcount of 51–100. The company is backed by domestic and foreign venture funds including Qiming Venture Partners, LYZZ Capital, and TF Capital, and has been recognized repeatedly on Great Wall Consultants' "Potential Unicorn" lists and as a Jiangsu Province technology-based enterprise.

The company's commercial and clinical centerpiece is Zorifertinib (泽瑞尼® / 盐酸佐利替尼片, originally AZD3759), a next-generation EGFR tyrosine kinase inhibitor approved and listed in China's national medical insurance (医保) as of July 2025. It is a Category 1 new drug (1类新药) supported by the National Major Project for New Drug Innovation, indicated for first-line treatment of EGFR-mutated (exon 19 deletion or L858R) locally advanced or metastatic non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastases. Its differentiating technical claim is 100% blood-brain barrier penetration enabled by a non-efflux-protein-substrate molecular design, validated in the Phase 3 EVEREST / CTONG1702-Arm 8 trial (published in The Lancet EClinicalMedicine, September 2023). The company also maintains an early-stage cell therapy pipeline — universal off-the-shelf Memory NK cells and fratricide-resistant CAR-T cells targeting solid tumors, T-cell malignancies, AML, and multiple myeloma — developed through an exclusive collaboration with Wugen Inc. announced in 2021.

Alpha Biopharma generates revenue through pharmaceutical product sales of Zorifertinib via direct distribution to hospital pharmacies and oncology centers across China, prescribed by oncologists. Pricing is not publicly disclosed and follows a prescription-based channel model; revenue mechanics are anchored to a single approved product serving one narrow indication (EGFR-mutant NSCLC with CNS metastases). The company has raised approximately $93.9 million in cumulative disclosed funding across four rounds from 2018 through 2024, and is led by founder Liu Zhonghai with James Liu (COO) and Joan Cai (CMO).

Short descriptiontext

Alpha Biopharma is a China-based clinical-stage biopharmaceutical company developing Zorifertinib, a first-in-class EGFR TKI with 100% blood-brain barrier penetration for EGFR-mutant NSCLC with CNS metastases, plus a cell therapy pipeline via its Wugen Inc. partnership.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology pharmaceuticals, EGFR-TKI drugs, cell therapy platforms, NSCLC treatment, innovative drug development
Industry3 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue generated from commercialized drug products, specifically Zorifertinib (泽瑞尼, generic name:盐酸佐利替尼片) which has been approved and included in medical insurance for treatment of EGFR-mutant NSCLC with CNS metastases.

alphabiopharma.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Alpha Biopharma is a clinical-stage biopharmaceutical company that develops and commercializes innovative oncology drugs, led by Zorifertinib (泽瑞尼®/AZD3759), a next-generation EGFR TKI for first-line treatment of EGFR-mutant NSCLC with CNS metastases. The company also develops universal off-the-shelf Memory NK cell and CAR-T cell therapies in partnership with Wugen Inc. for solid tumors, T-cell malignancies, AML, and Multiple Myeloma.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 100% blood-brain barrier penetration rate
+2 more records
Product overview1 text field

Alpha Biopharma (晨泰医药) operates two main product lines: (1) Marketed drug: Zorifertinib (泽瑞尼®/AZD3759), a next-generation EGFR TKI for EGFR mutation-positive NSCLC with CNS metastases, featuring 100% blood-brain barrier penetration; (2) Cell therapy pipeline: Universal 'off-the-shelf' Memory NK cells and CAR-T cells developed in partnership with Wugen Inc., targeting solid tumors, T-cell malignancies, AML, and Multiple Myeloma.

Product and service2 records
1Zorifertinib (泽瑞尼®)
CategorySmall molecule oncology drug
Description

Next-generation EGFR TKI drug (generic name: 盐酸佐利替尼片) for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR 19 exon deletion or 21 (L858R) substitution mutations and accompanied by CNS metastases. Features 100% blood-brain barrier penetration via a non-efflux protein substrate design. Available in 50mg and 100mg dosages; supported by China's National Major Project for New Drug Innovation as a Category 1 new drug.

2Universal Memory NK Cell Therapy
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-09
Description

Exclusive license and collaboration agreement with Wugen Inc., a clinical-stage biotechnology company developing novel universal natural killer (NK) and T-cell therapies for cancer treatment. Alpha Biopharma expanded its pipeline to manufacture universal 'off-the-shelf' Memory NK and CAR-T cells for treatment of solid tumors, T-cell malignancies, Acute Myeloid Leukemia, and Multiple Myeloma. This partnership gives Alpha Biopharma access to Wugen's innovative cell therapy platform technology.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Emerging oncology-focused biopharma developing next-generation targeted therapies including EGFR-TKIs (firmonertinib). Comparable as a focused EGFR-TKI developer competing in adjacent segments of the NSCLC treatment landscape.

TypeDirect peer
Description

China-based oncology-focused biotech with both small-molecule and biologics pipeline including lung cancer assets. Comparable in targeting NSCLC indications and pursuing NRDL access for innovative oncology therapies.

TypeDirect peer
Description

China-based biopharma commercializing innovative oncology biologics and small molecules (e.g., PD-1, biosimilars). Comparable in oncology focus, NRDL-driven commercialization model, and integrated clinical-to-commercial pipeline strategy.

4Genor Biopharma
TypeDirect peer
Description

China-focused oncology and immunology biopharma with a pipeline spanning innovative and biosimilar candidates. Comparable in Chinese hospital-channel commercialization and oncology pipeline strategy.

5Hansoh Pharmaceutical
TypeDirect peer
Description

Leading Chinese oncology biopharma developing EGFR-TKIs (e.g., furmonertinib) and other targeted therapies. Comparable as a China-domiciled, hospital-channel-driven oncology innovator with both marketed products and pipeline assets.

TypeBroad incumbent
Description

Originated AZD3759 (Zorifertinib) and markets Tagrisso (osimertinib), the dominant EGFR-TKI globally and in China. Directly competes with Alpha Biopharma in EGFR-mutant NSCLC and shapes the standard of care Zorifertinib must outperform.

TypeBroad incumbent
Description

Large Chinese oncology biotech with multiple approved targeted therapies (e.g., Brukinsa, Tevimbra) and a global commercial footprint. Comparable as a Chinese innovator that has scaled oncology drugs from clinical development to commercialization.

TypeDirect peer
Description

China-based biotech developing novel antibodies and bispecifics for oncology, including lung cancer candidates. Comparable in Chinese oncology innovation focus, NRDL strategy, and bispecific/antibody pipeline depth.

TypeDirect peer
Description

Chinese biopharma with strong oncology pipeline including PD-1 and targeted therapies. Comparable as a Chinese innovation-focused oncology company with NRDL participation and integrated clinical development.

TypeOthers
Description

US-based clinical-stage biotech and Alpha Biopharma's exclusive partner for Universal Memory NK and CAR-T cell therapy platforms. Highly relevant not as a competitor but as the technology partner whose platforms underpin Alpha Biopharma's cell therapy pipeline.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alpha Biopharma

Oncology Pharmaceuticalsalphabiopharma.com

Alpha Biopharma is a China-based clinical-stage biopharmaceutical company developing Zorifertinib, a first-in-class EGFR TKI with 100% blood-brain barrier penetration for EGFR-mutant NSCLC with CNS metastases, plus a cell therapy pipeline via its Wugen Inc. partnership.

What Alpha Biopharma does

Alpha Biopharma (晨泰医药 / Jiangsu Chentai Pharmaceutical Technology Co., Ltd.) is a China-based, privately held clinical-stage biopharmaceutical company founded in 2017. It specializes in innovative oncology drugs from clinical development through commercialization, with operations concentrated in mainland China (offices in Shanghai and Beijing; ICP-registered in Jiangsu) and a headcount of 51–100. The company is backed by domestic and foreign venture funds including Qiming Venture Partners, LYZZ Capital, and TF Capital, and has been recognized repeatedly on Great Wall Consultants' "Potential Unicorn" lists and as a Jiangsu Province technology-based enterprise.

The company's commercial and clinical centerpiece is Zorifertinib (泽瑞尼® / 盐酸佐利替尼片, originally AZD3759), a next-generation EGFR tyrosine kinase inhibitor approved and listed in China's national medical insurance (医保) as of July 2025. It is a Category 1 new drug (1类新药) supported by the National Major Project for New Drug Innovation, indicated for first-line treatment of EGFR-mutated (exon 19 deletion or L858R) locally advanced or metastatic non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastases. Its differentiating technical claim is 100% blood-brain barrier penetration enabled by a non-efflux-protein-substrate molecular design, validated in the Phase 3 EVEREST / CTONG1702-Arm 8 trial (published in The Lancet EClinicalMedicine, September 2023). The company also maintains an early-stage cell therapy pipeline — universal off-the-shelf Memory NK cells and fratricide-resistant CAR-T cells targeting solid tumors, T-cell malignancies, AML, and multiple myeloma — developed through an exclusive collaboration with Wugen Inc. announced in 2021.

Alpha Biopharma generates revenue through pharmaceutical product sales of Zorifertinib via direct distribution to hospital pharmacies and oncology centers across China, prescribed by oncologists. Pricing is not publicly disclosed and follows a prescription-based channel model; revenue mechanics are anchored to a single approved product serving one narrow indication (EGFR-mutant NSCLC with CNS metastases). The company has raised approximately $93.9 million in cumulative disclosed funding across four rounds from 2018 through 2024, and is led by founder Liu Zhonghai with James Liu (COO) and Joan Cai (CMO).

Alpha Biopharma firmographics

Firmographics
Name
Alpha Biopharma
Legal name
江苏晨泰医药科技有限公司
Website
https://alphabiopharma.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Alpha Biopharma is a China-based clinical-stage biopharmaceutical company developing Zorifertinib, a first-in-class EGFR TKI with 100% blood-brain barrier penetration for EGFR-mutant NSCLC with CNS metastases, plus a cell therapy pipeline via its Wugen Inc. partnership.
Ownership category
akta.pro rank

Alpha Biopharma industry classification

Industry
Product category
Oncology Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Oncology pharmaceuticals
  • EGFR-TKI drugs
  • Cell therapy platforms
  • NSCLC treatment
  • Innovative drug development

Where Alpha Biopharma is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices2 records

Markets served

Alpha Biopharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Revenue generated from commercialized drug products, specifically Zorifertinib (泽瑞尼, generic name:盐酸佐利替尼片) which has been approved and included in medical insurance for treatment of EGFR-mutant NSCLC with CNS metastases.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Alpha Biopharma product offering

Product offering

Core offering

Alpha Biopharma is a clinical-stage biopharmaceutical company that develops and commercializes innovative oncology drugs, led by Zorifertinib (泽瑞尼®/AZD3759), a next-generation EGFR TKI for first-line treatment of EGFR-mutant NSCLC with CNS metastases. The company also develops universal off-the-shelf Memory NK cell and CAR-T cell therapies in partnership with Wugen Inc. for solid tumors, T-cell malignancies, AML, and Multiple Myeloma.

Product overview

Alpha Biopharma (晨泰医药) operates two main product lines: (1) Marketed drug: Zorifertinib (泽瑞尼®/AZD3759), a next-generation EGFR TKI for EGFR mutation-positive NSCLC with CNS metastases, featuring 100% blood-brain barrier penetration; (2) Cell therapy pipeline: Universal 'off-the-shelf' Memory NK cells and CAR-T cells developed in partnership with Wugen Inc., targeting solid tumors, T-cell malignancies, AML, and Multiple Myeloma.

Differentiator

Problem solved

Functional benefit

Products and services

  • Zorifertinib (泽瑞尼®) Next-generation EGFR TKI drug (generic name: 盐酸佐利替尼片) for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR 19 exon deletion or 21 (L858R) substitution mutations and accompanied by CNS metastases. Features 100% blood-brain barrier penetration via a non-efflux protein substrate design. Available in 50mg and 100mg dosages; supported by China's National Major Project for New Drug Innovation as a Category 1 new drug.
  • Universal Memory NK Cell Therapy

Quantifiable outcome

  • 100% blood-brain barrier penetration rate
  • +2 more outcomes

Companies that use Alpha Biopharma

Customer profile

Segments1 record

Ideal customer profiles1 record

Alpha Biopharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Alpha Biopharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Wugen Inc.coreStrategic or Co-development Partner · 9 March 2021Exclusive license and collaboration agreement with Wugen Inc., a clinical-stage biotechnology company developing novel universal natural killer (NK) and T-cell therapies for cancer treatment. Alpha Biopharma expanded its pipeline to manufacture universal 'off-the-shelf' Memory NK and CAR-T cells for treatment of solid tumors, T-cell malignancies, Acute Myeloid Leukemia, and Multiple Myeloma. This partnership gives Alpha Biopharma access to Wugen's innovative cell therapy platform technology.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Alpha Biopharma competitors and assessment

Company assessment

Emerging players

  • ArriVent Biopharma: Emerging oncology-focused biopharma developing next-generation targeted therapies including EGFR-TKIs (firmonertinib). Comparable as a focused EGFR-TKI developer competing in adjacent segments of the NSCLC treatment landscape.

Direct peers

  • Cstone Pharmaceuticals: China-based oncology-focused biotech with both small-molecule and biologics pipeline including lung cancer assets. Comparable in targeting NSCLC indications and pursuing NRDL access for innovative oncology therapies.
  • Innovent Biologics: China-based biopharma commercializing innovative oncology biologics and small molecules (e.g., PD-1, biosimilars). Comparable in oncology focus, NRDL-driven commercialization model, and integrated clinical-to-commercial pipeline strategy.
  • Genor Biopharma: China-focused oncology and immunology biopharma with a pipeline spanning innovative and biosimilar candidates. Comparable in Chinese hospital-channel commercialization and oncology pipeline strategy.
  • Hansoh Pharmaceutical: Leading Chinese oncology biopharma developing EGFR-TKIs (e.g., furmonertinib) and other targeted therapies. Comparable as a China-domiciled, hospital-channel-driven oncology innovator with both marketed products and pipeline assets.
  • Akeso (AkesoBiopharma): China-based biotech developing novel antibodies and bispecifics for oncology, including lung cancer candidates. Comparable in Chinese oncology innovation focus, NRDL strategy, and bispecific/antibody pipeline depth.
  • Junshi Biosciences: Chinese biopharma with strong oncology pipeline including PD-1 and targeted therapies. Comparable as a Chinese innovation-focused oncology company with NRDL participation and integrated clinical development.

Broad incumbents

  • AstraZeneca: Originated AZD3759 (Zorifertinib) and markets Tagrisso (osimertinib), the dominant EGFR-TKI globally and in China. Directly competes with Alpha Biopharma in EGFR-mutant NSCLC and shapes the standard of care Zorifertinib must outperform.
  • BeiGene: Large Chinese oncology biotech with multiple approved targeted therapies (e.g., Brukinsa, Tevimbra) and a global commercial footprint. Comparable as a Chinese innovator that has scaled oncology drugs from clinical development to commercialization.

Others

  • Wugen Inc. US-based clinical-stage biotech and Alpha Biopharma's exclusive partner for Universal Memory NK and CAR-T cell therapy platforms. Highly relevant not as a competitor but as the technology partner whose platforms underpin Alpha Biopharma's cell therapy pipeline.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Alpha Biopharma social profiles

Digital presence

Alpha Biopharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alpha Biopharma leadership team

Management profile

Number of profiles

Profiles3 records

Alpha Biopharma funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alpha Biopharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alpha Biopharma

What does Alpha Biopharma do?

Alpha Biopharma is a clinical-stage biopharmaceutical company that develops and commercializes innovative oncology drugs, led by Zorifertinib (泽瑞尼®/AZD3759), a next-generation EGFR TKI for first-line treatment of EGFR-mutant NSCLC with CNS metastases. The company also develops universal off-the-shelf Memory NK cell and CAR-T cell therapies in partnership with Wugen Inc. for solid tumors, T-cell malignancies, AML, and Multiple Myeloma.

Is Alpha Biopharma a public or private company?

Alpha Biopharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Alpha Biopharma founded?

Alpha Biopharma was founded in 2017. It employs 1 to 10 people.

Where is Alpha Biopharma based?

Alpha Biopharma is headquartered in Shanghai, China, in the Asia region.

How does Alpha Biopharma make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Alpha Biopharma's main competitors?

ArriVent Biopharma is listed as an emerging player. Direct peers are Cstone Pharmaceuticals, Innovent Biologics, Genor Biopharma, Hansoh Pharmaceutical, Akeso (AkesoBiopharma) and Junshi Biosciences. Broad incumbents are AstraZeneca and BeiGene. Wugen Inc. is listed as an others.

Does Alpha Biopharma have an API?

No public API is recorded for Alpha Biopharma.

What industry is Alpha Biopharma in?

Alpha Biopharma's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAAABAD, NK Cell Therapies. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioWorldChina’s Alpha Biopharma seeks new drug status for EGFR-TKI productAlpha Biopharma submitted an NDA in China for zorifertinib, a next-generation EGFR-TKI for advanced EGFR-mutated non-small-cell lung cancer with CNS metastases. The company states zorifertinib is the first EGFR-TKI tested in a clinical study for this patient population.PR NewswireAlpha Biopharma Submits New Drug Application for Zorifertinib, a Next-Generation EGFR-TKI to Treat EGFR-mutated NSCLC Patients with CNS MetastasesAlpha Biopharma announced that China's Center for Drug Evaluation (CDE) has accepted its New Drug Application (NDA) for Zorifertinib, a next-generation EGFR-TKI designed to treat advanced EGFR-mutated non-small cell lung cancer patients with central nervous system metastases. The EVEREST phase II/III clinical trial enrolled 492 patients across 55 sites in mainland China, Taiwan, South Korea, and Singapore, demonstrating that Zorifertinib significantly reduced disease progression risk and showed effective CNS penetration with a safety profile comparable to other approved EGFR-TKIs. If approved, Zorifertinib would become the first EGFR-TKI specifically validated for this difficult-to-treat patient population with CNS involvement.PR NewswireAlpha Biopharma Announces Completion of its EVEREST Phase II/III Clinical Study of Zorifertinib in Non-Small Cell Lung Cancer Patients with Central Nervous System MetastasesAlpha Biopharma announced the completion of the last patient last visit (LPLV) in its international multicenter EVEREST Phase II/III clinical study of Zorifertinib for first-line treatment of EGFRm+ non-small cell lung cancer patients with central nervous system metastases. The study enrolled 492 patients across 55 sites in Chinese mainland, Taiwan, South Korea, and Singapore, with top-line data expected around the end of 2022, potentially leading to a New Drug Application submission to China's National Medical Products Administration.PR NewswireWugen Announces Exclusive Partnership Agreement With Alpha Biopharma in Asia For Cell Therapies to Treat CancerWugen Inc. announced an exclusive license and collaboration with Alpha Biopharma to manufacture, develop, and commercialize allogeneic cell products in Asia, including China, Hong Kong, Macao, Taiwan, and Singapore. The products target solid tumors, T-cell malignancies, AML, and multiple myeloma, with Alpha Biopharma handling development and commercialization.